Ingestion of Exopolymers from Aureobasidium pullulans Reduces the Duration of Cold and Flu Symptoms: A Randomized, Placebo-Controlled Intervention Study

Evidence-based Complementary and Alternative Medicine : ECAM
Jong-Min LimJae-Suk Choi

Abstract

The objective of the study was to assess the efficacy of exopolymers from Aureobasidium pullulans (EAP) on the incidence of colds and flu in healthy adults. We conducted a randomized, double-blind, placebo-controlled study at the onset of the influenza season. A total of 76 subjects (30-70 years of age) were recruited from the general population. The subjects were instructed to take one capsule per day of either EAP or a placebo for a period of 8 weeks. The duration of cold and flu symptoms, a primary variable in assessing effectiveness, and serum cytokine levels as well as WBC counts as secondary variables were also evaluated. EAP was associated with a statistically significant decrease in the duration of cold and flu symptoms, a primary variable in assessing effectiveness. Although cold and flu symptom levels were not significantly different at a significance level of 5%, the cold and flu symptom levels of the EAP group were less severe compared to the placebo group. No statistically significant changes of serum cytokine levels as well as WBC counts were observed. The results showed that EAP is a useful pharmaceutical and functional food material for preventing and treating colds and flu.

References

Mar 1, 1982·Infection and Immunity·J L BenachJ A Cook
Feb 18, 1998·European Journal of Clinical Investigation·W L BlokM B Katan
Jan 1, 1997·Microbiology and Immunology·A EstradaB Laarveld
Mar 18, 2000·The Journal of Nutrition·K L Erickson, N E Hubbard
Jun 5, 2001·Bioscience, Biotechnology, and Biochemistry·J N LeeC W Kim
Oct 8, 2003·Current Pharmaceutical Biotechnology·Yoshinori KatoYoshiharu Machida
Mar 29, 2006·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Janet E McElhaneyJacqueline J Shan
Jul 27, 2010·Current Opinion in Clinical Nutrition and Metabolic Care·Xin ZhouGeorge A Kuchel
Feb 4, 2011·Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine·Sunil KumarDinesh Kumar
Feb 9, 2012·BMC Complementary and Alternative Medicine·Ki-Chan HaChang-Seop Lee
Oct 16, 2013·Trends in Biotechnology·Hesham A El Enshasy, Rajni Hatti-Kaul
May 27, 2014·Emerging Infectious Diseases·Ziad A MemishChristian Drosten
Oct 22, 2014·Annals of Translational Medicine·Vaclav VetvickaVlastimil Král
Nov 3, 2016·World Journal of Microbiology & Biotechnology·Katsuki HirabayashiSachio Hayashi
Dec 17, 2016·Emerging Infectious Diseases·Paola Cristina ResendeMarilda M Siqueira
May 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew T Y WongUNKNOWN Central Committee on Infectious Diseases and Emergency Response, Hospital Authority, Hong Kong Special Administrative Region
Dec 1, 2014·Journal of Food and Drug Analysis·Yong SunLiyan Zhao

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

Excel
SAS

Related Concepts

Related Feeds

Acute viral rhinopharyngitis

Acute viral rhinopharyngitis, also known as "common cold", is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx. Discover the latest research on acute viral rhinopharyngitis here.